X-ZELL Cryophore™ Panels achieve IVDR CE Mark Singapore, April 2026 – X-ZELL is proud to announce that its new Cryophore™ multiplex antibody panels have achieved IVDR CE marking, representing an important milestone in bringing multiplex immunostaining into routine...
New publication highlights potential of multiplexing in effusion and FNA cytology Ljubljana, March 2026 – A newly published peer-reviewed paper from the Department of Cytopathology at the Institute of Oncology Ljubljana (IOL), Slovenia, reports promising preliminary...
X-ZELL launches first Cryophore™ Multiplex Antibody Panels for Cytology Singapore, March 2026 – X-ZELL is proud to announce the commercial launch of its first line of Cryophore™ multiplex antibody panels. Previewed at the 2025 International Congress of Cytology, the...
Early adopters share first-hand experience with Cryoimmunostaining™ technology Halle (Saale), November 2025 – After breaking new ground last year by featuring Cryoimmunostaining™ in the official scientific programme for the first time, the 2025 Seminar on Clinical...
New data confirms routine utility of Cryoimmunostaining™ for effusion and FNA samples Ljubljana, October 2025 – New clinical data on multiplex Cryoimmunostaining™ took centre stage at an international science conference in Ljubljana, Slovenia, where digital cytology...
X-ZELL previews world’s first expert-vetted multiplex panels for cytopathology Florence , May 2025 – X-ZELL is proud to announce the new Cryophore™ range of standardized multiplex antibody panels, developed in close collaboration with leading experts and WHO guideline...
